Reindarstellung der Hormone aus dem Corpus luteum (II. Mitteil.)

Slotta, K. H.; Ruschig, Heinrich; Fels, E

doi:10.1002/cber.19340670933

Cited by 29 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Progesterone was discovered in 1934 by multiple groups. 23,24 The first orally active progestin was synthesized in 1938 and named “ethisterone” and was significantly androgenic. 25 The same group later synthesized estradiol, termed “ethynylestradiol,” 26 which was widely used for decades including in the care of transgender women.…”

Section: Historical Perspectivesmentioning

confidence: 99%

Advances in the Care of Transgender Children and Adolescents

Shumer

Nokoff

Spack

2016

Advances in Pediatrics

View full text Add to dashboard Cite

Children and adolescents with gender dysphoria are presenting for medical attention at increasing rates. Standards of Care have been developed which outline appropriate mental health support and hormonal interventions for transgender youth. This article defines terminology related to gender identity, reviews the history of medical interventions for transgender persons, outlines what is known about gender identity development, and reviews mental health disparities faced by this patient population. We provide an overview of medical management options for transgender adolescents meeting diagnostic criteria for gender dysphoria including pubertal suppression, cross-sex hormones, longitudinal screening and anticipatory guidance. We describe current challenges in the field and provide information about how care is currently being provided in the US and Canada. We conclude with 5 brief case examples.

show abstract

Section: Historical Perspectivesmentioning

confidence: 99%

Advances in the Care of Transgender Children and Adolescents

Shumer

Nokoff

Spack

2016

Advances in Pediatrics

View full text Add to dashboard Cite

show abstract

“…Clauberg later developed a modified assay that eliminated the need for castration [21]. The isolation of purified crystalline corpus luteum hormone from sow ovaries was achieved by various groups in 1934 by applying these assays to identify the active fractions [22][23][24][25]. Ovaries from 10-15 sows were necessary to isolate enough purified hormone to induce the characteristic physiological changes in the uterus of one rabbit.…”

Section: Progesterone Receptor Researchmentioning

confidence: 99%

Nuclear Receptors as Drug Targets: A Historical Perspective of Modern Drug Discovery

Ottow

Weinmann

2008

Methods and Principles in Medicinal Chemistry

View full text Add to dashboard Cite

“…George Corner and Willard Allen demonstrated that injections of corpora luteal extracts into rabbits, oophorectomised shortly after mating, prevented abortion, which provided further proof for a second hormone (Allen & Corner 1930). Attempts to isolate the active principle from these extracts were successful in 1934, when four laboratories independently announced the isolation of crystalline progesterone (Allen & Wintersteiner 1934, Butenandt & Westphal 1934, Hartmann & Wettstein 1934, Slotta et al 1934. At the Second International Conference on Standardisation of Sex Hormones, the corpus luteum hormone was named 'progesterone', due to its ability to maintain gestation.…”

Section: Progesteronementioning

confidence: 99%

Postmenopausal hormone therapy: from monkey glands to transdermal patches

Davis

Dinatale²,

Rivera-Woll³

et al. 2005

Journal of Endocrinology

View full text Add to dashboard Cite

The climacteric is not a condition of the modern age, although with increased life expectancy over the centuries, more women will experience this physiological transition. As women are living longer there is a greater expectation that good health will be maintained through to the late decade. Thus the potential long-term adverse health consequences of using hormonal therapies (HTs) to alleviate menopausal symptoms are of considerable concern for women and medical practitioners. This concern is often the basis for a decision whether or not to use HT.We have reviewed the history of knowledge of the menopause and the development of HT for the treatment of climacteric complaints. We have also summarised the current evidence for specific benefits and risks of HT. Data indicate that postmenopausal HT is appropriate for the management of vasomotor symptoms, but that HT should not be prescribed for the prevention of cardiovascular disease or dementia. HT does prevent bone loss and osteoporotic fracture; however, use for this purpose remains controversial. The risk of breast cancer with HT varies according to the preparation used, such that oestrogen without concurrent progestin appears to convey little, or possibly even no significant breast cancer risk. There is insufficient information regarding the long-term use of non-oral HT, low-dose HT or novel compounds such as tibolone or the selective oestrogen receptor modulators with respect to breast cancer and cardiovascular risk for specific recommendations to be made.

show abstract

Reindarstellung der Hormone aus dem Corpus luteum (II. Mitteil.)

Cited by 29 publications

References 5 publications

Advances in the Care of Transgender Children and Adolescents

Advances in the Care of Transgender Children and Adolescents

Nuclear Receptors as Drug Targets: A Historical Perspective of Modern Drug Discovery

Postmenopausal hormone therapy: from monkey glands to transdermal patches

Contact Info

Product

Resources

About